Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses why predicting venetoclax response in patients with acute myeloid leukemia (AML) remains a challenge in the field, and further outlines some genomic-related hypotheses as to why some patients may not respond to this agent. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.